NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.
Enhancingthe body’s healing response
Rebalancingthe immune system
Unlockingthe power of VSELs
NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.
NeoStem Profile by BTV
Business Television (BTV) visited NeoStem to speak with Dr. Robin Smith, Chairman and CEO, and Dr. Douglas Losordo,Chief Medical Officer,
News + EventsNeoStem Awarded 2014 Cell Therapeutics Technology Leadership Award from Frost & Sullivan July 14, 2014 -Learn MoreNeoStem Appoints Steven M. Klosk to Board of Directors July 8, 2014 - Learn MoreNeoStem’s Cancer Immunotherapy Experts to Present at Novel Cancer Therapeutics Summit 2014 June 30, 2014 - Learn More
On July 1st, approximately 14,456 shares of the Company’s common stock were purchased by employees of th.... Read More